Product Indication Status Partner
Lyrica Neuropathic pain and Approved in Europe;
epilepsy approvable in the U.S.
Parecoxib Pain Approved outside the U.S.;
NDA submission expected by
year end
Macugen Age-related macular Dec. 17 PDUFA date Eyetech (EYET)
degeneration
Indiplon Insomnia Under FDA review Neurocrine (NBIX)
Lasofoxifene Osteoporosis Under FDA review Ligand (LGND)
Zithromax SR Bacterial infection Under FDA and German
review
Exubera Diabetes Under European review sanofi-aventis (Euronext:SAN; SNY);
Nektar (NKTR)
Daxas Chronic obstructive pulmonary Under European review Altana (FSE:ALT; AAA)
disease (COPD) and asthma
Sildenafil (Viagra) Pulmonary arterial Under FDA review
hypertension (PAH)
Torcetrapib-atorvastatin Coronary heart disease Ph III
Varenicline Nicotine addiction Ph III
Asenapine Schizophrenia Ph III Organon
Zithromax-chloroquine Resistant malaria Ph III
UK-427,857 HIV Ph III
SU-11248 Gastrointestinal Ph II Sugen (acquired by
stromal tumors (GIST) PFE in 1999)
ETC-216 Lipid disorders and Ph II Esperion (acquired by
atherosclerosis PFE in February)
CP-675,206 Cancer Ph II Abgenix (ABGX)
AG-13736 Cancer Ph II
CP-945,598 Alcohol and Ph I
nicotine addiction
Capravirine HIV NA
Edotecarin Cancer NA
AG-13958 Age-related macular NA
degeneration